van der Galiën, H T <br/><br/>
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  01 2019 
 - 151-152 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdy482  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse<br/>Progression-Free Survival<br/>Randomized Controlled Trials as Topic<br/>Rituximab